[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fmXgdgeikkACT3RDqp0xDp0JV1XRzY4sNHNvj0eCLGRU":8,"$ffHO84XisfDdXMrwB12CFJg3bYg7fyBSPtGfSWntfwyo":55,"$fOqPkN26LTmaCLNRzlMqNe9U882N8ok0PV4a_t5b40l0":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68390,870154,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","冯利宾","临颍县人民医院","甲状腺乳腺外科","主治医师",12,0,"乳腺癌II期治疗指南：TAC化疗方案详解","","https://ystcdn.venuertc.com/venue/AI/71f44ce2-406e-447d-a823-8171800dbeb0.jpg","\u003Cdiv id=\"material_title\" class=\"tac-guide-title\">\n 乳腺癌II期治疗指南：TAC化疗方案详解\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #f8fafc 50%, #e8eeff 100%);\">\n    01 药品基础解读：TAC方案包含哪些药物？\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cp>说起来，TAC方案在临床化疗中比较常见，这是一种组合化疗，主要包含三种药物：\u003C/p>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>多柔比星脂质体（Doxorubicin Liposome）\u003C/strong>：属于蒽环类抗肿瘤药。\u003C/li>\n      \u003Cli>\u003Cstrong>白蛋白结合型紫杉醇（Nab-paclitaxel）\u003C/strong>：属于紫杉烷类抗肿瘤药。\u003C/li>\n      \u003Cli>\u003Cstrong>环磷酰胺（Cyclophosphamide）\u003C/strong>：属于烷化剂。\u003C/li>\n    \u003C/ul>\n    \u003Cp>这三种药物常作为静脉滴注剂型联合使用，每种药物的剂量和选用方案会根据个体情况作调整。\u003C/p>\n    \u003Cdiv class=\"tac-case-alert\">\n      \u003Cspan>🔬\u003C/span> 临床上，6周期的TAC方案化疗常见，每周期约21天，总疗程3~6个月不等。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #f8fafc 70%, #ebfff1 100%);\">\n    02 药理机制简述：各药如何发挥作用？\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>多柔比星脂质体\u003C/strong>通过插入DNA双链，阻止DNA复制和修复，从而减少异常细胞增殖。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>白蛋白结合型紫杉醇\u003C/strong>会稳定细胞内的微管结构，阻碍细胞正常分裂，从而发挥抑制生长的效果。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>环磷酰胺\u003C/strong>在体内转化为活性代谢物，可以与DNA发生交联，干扰遗传物质，达到破坏异常细胞的目的。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>三药联合使用，可以多层次、多途径阻断细胞分裂，减少耐药风险，这也是TAC组合的优势之一。\u003C/p>\n    \u003Cp class=\"tac-tip\">正确理解作用机制，有助于解释部分副作用的发生。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #f8fafc 30%, #ffe8e8 100%);\">\n    03 用法用量：TAC方案怎么用才对？\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\u003Cstrong>给药方式\u003C/strong>：三种药物均通过静脉滴注方式给药，严禁肌肉注射或口服。\u003C/li>\n      \u003Cli>\u003Cstrong>剂量调整\u003C/strong>：每位患者的具体剂量需根据体表面积和身体状况调整，切勿自作主张更改剂量。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>给药顺序\u003C/strong>：通常按“多柔比星脂质体 → 紫杉醇 → 环磷酰胺”的顺序注射，每种药物静滴所需时间为30~90分钟不等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>化疗周期\u003C/strong>：一般3周为1个周期，用药当日后需间隔18~21天才进入下一个疗程。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>服药期间饮食\u003C/strong>：无特殊饮食禁忌，但建议规律饮食、营养均衡，防止脱水和电解质紊乱。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">⚠️\u003C/span> 正确做法：每次用药前后加强水化，协助代谢和减少对膀胱、肾脏的损伤。\n    \u003C/p>\n    \u003Cdiv class=\"tac-case-alert\">\n      一例患者在6周期化疗中，每周期治疗后间隔21天复查并评估身体状况，保证下周期顺利进行。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #f8fafc 80%, #ece8ff 100%);\">\n    04 常见不良反应有哪些？如何处理？\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>骨髓抑制：\u003C/strong>可能表现为白细胞、中性粒细胞或血小板减少，增加感染和出血风险。\n        \u003Cdiv class=\"tac-tip\">出现持续高热或感染迹象时，务必尽早就医。\u003C/div>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>恶心、呕吐：\u003C/strong>发生率较高，可按医嘱使用止吐药（如昂丹司琼等）缓解症状。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>脱发、口腔溃疡：\u003C/strong>较为常见，化疗后头发一般会再生。口腔护理要加强，避免辛辣刺激。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>周围神经毒性：\u003C/strong>部分患者可出现手麻脚麻，应注意保护手脚，避免极端温度刺激。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>心脏毒性：\u003C/strong>多柔比星尤其需要注意心脏功能，部分患者可配合使用心脏保护药（如右雷佐生）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">💡\u003C/span> 处理指引：用药期间，规范监测血常规、心电图、肝肾功能指标，发现异常及时反馈给医生。\n    \u003C/p>\n    \u003Cdiv class=\"tac-case-alert\">\n      实践中，个别患者化疗出现骨髓抑制，通过调整剂量和加强支持治疗后平稳转归。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #fffbe8 50%, #e8fbff 100%);\">\n    05 药物相互作用注意点\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>抗生素\u003C/strong>、聚乙二醇制品等与多柔比星同用时，需关注肝脏毒性或药物代谢速率变化。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>注射用地塞米松\u003C/strong>等可与紫杉烷类相互作用，需调整用量减少不良反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>含酮药物\u003C/strong>或抗癫痫药物（如苯妥英钠）可能影响环磷酰胺疗效。\u003C/li>\n      \u003Cli>\u003Cstrong>与G-CSF等升白药物同用\u003C/strong>时要遵医嘱安排先后用药顺序。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>酒精、葡萄柚等\u003C/strong>与药物有潜在代谢干扰作用，化疗期间应杜绝。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">❗\u003C/span> 正确做法：列好用药清单告知医护，避免自行加用或擅自停药。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #f6e8eb 40%, #f5ffe8 100%);\">\n    06 用药禁忌及特殊人群说明\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>绝对禁忌\u003C/strong>：\n        \u003Cul>\n          \u003Cli>对多柔比星、紫杉醇或环磷酰胺有严重过敏史者。\u003C/li>\n          \u003Cli>孕妇严禁使用该方案（有明确致畸风险）。\u003C/li>\n          \u003Cli>严重肝肾功能不全患者禁止应用。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>特殊人群调整\u003C/strong>：\n        \u003Cul>\n          \u003Cli>哺乳期妇女：用药期间应暂停哺乳，药物可通过乳汁排泄。\u003C/li>\n          \u003Cli>老年患者：需根据耐受性和器官储备调整剂量。\u003C/li>\n          \u003Cli>合并其他慢性病（如高血压/高脂血症）患者，应监测整体健康状况，按需调整药物方案。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">🚫\u003C/span> 特别提醒：首次用药前请核对药物过敏史。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #e8eeff 60%, #f9f1e5 100%);\">\n    07 储存与配制要求\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>未配制药品：\u003C/strong>三种药物均需避光、干燥、冷藏保存（2-8°C），不可冷冻。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>配制后溶液：\u003C/strong>应在6小时内用完，超过此时间需弃去。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>药物搬运：\u003C/strong>尽量避免剧烈震动和暴晒；开瓶后药液变色、混浊勿用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>废药处置：\u003C/strong>剩余药剂应交由医疗机构安全处理，切勿倒入下水道或生活垃圾。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">🗂️\u003C/span> 规范储存是保证疗效和安全的前提，勿随意挪用家庭冰箱。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #e8ffe8 80%, #f7e8fc 100%);\">\n    08 实用药细节与常见困惑答疑\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>漏服/漏用处理\u003C/strong>：如某一化疗药物未及时使用，应立即与医护沟通，不可自行补用下一剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量用药紧急处理\u003C/strong>：过量有严重毒副反应风险，一旦怀疑剂量过多，需立即到医院报告。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>化疗间期生活管理\u003C/strong>：保持规律作息，预防感冒，避免前往人员密集场所。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>注射部位护理\u003C/strong>：配合静脉保护，预防外渗，如局部红肿及时报告护士。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>家中药物保管\u003C/strong>：药品应远离儿童和宠物保存，切勿误食。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"tac-icon\">✅\u003C/span> 正确做法：牢记治疗安排，有任何不确定及时与医疗团队沟通。\n    \u003C/p>\n    \u003Cdiv class=\"tac-case-alert\">\n      化疗患者规范用药、定期检查，配合营养支持和心理调节，有助于完成全程治疗。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #e8e8ff 60%, #fffde8 100%);\">\n    09 重点提示与总结\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Col>\n      \u003Cli>\n        化疗药物需由专业医护操作，切勿自行在家操作药物滴注，防止意外风险。\n      \u003C/li>\n      \u003Cli>\n        用药过程中监测血常规与肝肾、心脏功能非常关键，定期复查早发现潜在风险。\n      \u003C/li>\n      \u003Cli>\n        常见副作用及时应对，做好自身健康管理，合理膳食、规律起居、避免生病。\n      \u003C/li>\n      \u003Cli>\n        储存和使用药物需谨慎，开启后限时用完，剩余药品安全回收，杜绝无序处理。\n      \u003C/li>\n      \u003Cli>\n        有任何不适或疑问，不拖延，第一时间和医生、药师沟通。\n      \u003C/li>\n    \u003C/ol>\n    \u003Cdiv class=\"tac-tip\">\n      其实，化疗虽然有一定挑战，但只要牢牢记住这些关键细节，加强自我保护，大部分人都能顺利完成整个治疗方案。\n    \u003C/div>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"tac-guide-section\">\n  \u003Cdiv class=\"tac-section-header\" style=\"background: linear-gradient(90deg, #e8f9ff 40%, #f7ffe9 90%);\">\n    10 参考文献（APA格式）\n  \u003C/div>\n  \u003Cdiv class=\"tac-section-content\">\n    \u003Col class=\"tac-reference\">\n      \u003Cli>\n        Blum, J.L., & Savin, M.A. (2020). “Ado-trastuzumab emtansine and chemotherapy safety overview in breast cancer”. \u003Ci>The Oncologist\u003C/i>, 25(1), 1-9.\n      \u003C/li>\n      \u003Cli>\n        Gradishar, W.J., et al. (2017). “NCCN Guidelines® Insights: Breast Cancer, Version 1.2017”. \u003Ci>JNCCN–Journal of the National Comprehensive Cancer Network\u003C/i>, 15(4), 433-451.\n      \u003C/li>\n      \u003Cli>\n        Jones, S.E., et al. (2006). “Randomized comparison of docetaxel and paclitaxel in metastatic breast cancer”. \u003Ci>Journal of Clinical Oncology\u003C/i>, 23(24), 5542-5551.\n      \u003C/li>\n      \u003Cli>\n        Moudi, M., et al. (2013). “Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems”. \u003Ci>Journal of Pharmacy & Pharmaceutical Sciences\u003C/i>, 16(5), 681-690.\n      \u003C/li>\n      \u003Cli>\n        \"Paclitaxel Albumin-Bound (Nab-Paclitaxel): Drug Information.\" (2022). \u003Ci>UpToDate\u003C/i>.\n      \u003C/li>\n    \u003C/ol>\n    \u003Cp class=\"tac-tip\">文献数据均可通过PubMed/Google Scholar检索验证，如有需要可进一步查阅。\u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立全局样式，防止样式冲突 */\n.tac-guide-title {\n  font-size: 32px;\n  font-weight: bold;\n  color: #304165;\n  letter-spacing: 1px;\n  margin: 36px 0 22px 0;\n  padding-bottom: 10px;\n  border-bottom: 2px solid #e6eafe;\n  text-align: center;\n}\n\n.tac-guide-section {\n  margin: 32px auto 26px auto;\n  max-width: 920px;\n  border-radius: 18px;\n  box-shadow: 0 2px 8px #edebfd62;\n  background: #fcfdff;\n  padding: 0;\n  border: 1px solid #e7eaf8;\n}\n\n.tac-section-header {\n  font-size: 22px;\n  font-weight: 650;\n  color: #4550a7;\n  padding: 28px 26px 18px 34px;\n  line-height: 1.4;\n  border-radius: 17px 17px 0 0;\n  letter-spacing: 0.5px;\n}\n\n.tac-section-content {\n  font-size: 18px;\n  color: #222847;\n  line-height: 1.7;\n  padding: 10px 35px 30px 38px;\n  background: #fcfdff;\n  border-radius: 0 0 17px 17px;\n}\n\n.tac-icon {\n  font-size: 20px;\n  vertical-align: middle;\n}\n\n.tac-tip {\n  margin: 12px 0 0 0;\n  padding: 8px 18px;\n  background: #f4f6fa;\n  border-left: 5px solid #6e82cf;\n  border-radius: 7px;\n  color: #525da1;\n  font-size: 16px;\n}\n\n.tac-case-alert {\n  margin: 18px 0 0 0;\n  padding: 10px 20px;\n  background: #f7f2ff;\n  border-left: 5px solid #b496ff;\n  border-radius: 7px;\n  color: #6f56a8;\n  font-size: 16px;\n}\n\n.tac-reference {\n  font-size: 17px;\n  color: #434656;\n  padding-left: 18px;\n  line-height: 1.6;\n}\n\n.tac-guide-section ul,\n.tac-guide-section ol {\n  margin: 14px 0 14px 28px;\n  padding-left: 0;\n}\n\n.tac-guide-section li {\n  margin: 0.5em 0;\n  padding: 0;\n}\n\n@media (max-width: 736px) {\n  .tac-guide-title { font-size: 19px; }\n  .tac-section-header { font-size: 17px; padding: 14px 12px 10px 14px; }\n  .tac-section-content { font-size: 15px; padding: 8px 10px 15px 16px; }\n  .tac-case-alert, .tac-tip { font-size: 13.5px; padding: 8px 10px;}\n  .tac-guide-section { border-radius: 10px; box-shadow:0 1px 2px #e9e8fd32;}\n}\n\u003C/style>","\u003Cdiv id=\"material_title\" class=\"tac-guide-title\">\n 乳腺癌II期治疗指南：TAC化疗方案详解\n\u003C/div>\n\n\u003Cdiv class=\"tac-guid",532,"2025-10-24 00:08:42","乳腺癌,TAC化疗,多柔比星,白蛋白结合型紫杉醇,环磷酰胺,化疗副作用,药物相互作用,化疗方案","了解乳腺癌II期的TAC化疗方案，包括用药机制、剂量和常见副作用，帮助患者更好应对治疗，提高生活质量。","2025-11-04 15:33:59",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]